Preventative migraine treatment is certainly more of an art than science. While algorithms are helpful, they are merely guidelines that practitioners can reference. The cGRP inhibitors have been a game-changer in migraine prevention and I have thought about cGRP inhibitors more and more as first line especially given the now 5 years of safety data for erenumab-aooe. As the cGRP inhibitor market has grown with several that can be used for migraine prevention, I am developing a sense of which to use with whom. For example, I tend to use erenumab-aooe in younger patients with no hx of constipation.

Have you developed a strategy for deciding which cGRP to use with specific types of patients and if one cGRP is not effective, do you switch to another one?

Preventative migraine treatment is certainly more of an art than science. While algorithms are helpful, they are merely guidelines that practitioners can reference. The cGRP inhibitors have been a game-changer in migraine prevention and I have thought about cGRP inhibitors more and more as first line especially given the now 5 years of safety data for erenumab-aooe. As the cGRP inhibitor market has grown with several that can be used for migraine prevention, I am developing a sense of which to use with whom. For example, I tend to use erenumab-aooe in younger patients with no hx of constipation.



Have you developed a strategy for deciding which cGRP to use with specific types of patients and if one cGRP is not effective, do you switch to another one?

Preventative migraine treatment is certainly more of an art than science. While algorithms are helpful, they are merely guidelines that practitioners can reference. The cGRP inhibitors have been a game-changer in migraine prevention and I have thought about cGRP inhibitors more and more as first line especially given the now 5 years of safety data for erenumab-aooe. As the cGRP inhibitor market has grown with several that can be used for migraine prevention, I am developing a sense of which to use with whom. For example, I tend to use erenumab-aooe in younger patients with no hx of constipation.



Have you developed a strategy for deciding which cGRP to use with specific types of patients and if one cGRP is not effective, do you switch to another one?

Preventative migraine treatment is certainly more of an art than science. While algorithms are helpful, they are merely guidelines that practitioners can reference. The cGRP inhibitors have been a game-changer in migraine prevention and I have thought about cGRP inhibitors more and more as first line especially given the now 5 years of safety data for erenumab-aooe. As the cGRP inhibitor market has grown with several that can be used for migraine prevention, I am developing a sense of which to use with whom. For example, I tend to use erenumab-aooe in younger patients with no hx of constipation.



Have you developed a strategy for deciding which cGRP to use with specific types of patients and if one cGRP is not effective, do you switch to another one?